<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003288</url>
  </required_header>
  <id_info>
    <org_study_id>H1N1VAC-2009, Version 1</org_study_id>
    <secondary_id>2009-016456-43</secondary_id>
    <nct_id>NCT01003288</nct_id>
  </id_info>
  <brief_title>Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen</brief_title>
  <acronym>H1N1VAC</acronym>
  <official_title>Safety and Immunogenicity Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haukeland University Hospital has approximately 8000 employees many of whom will be in the
      front line to receive the pandemic A/H1N1 vaccine. We propose to conduct a safety and
      immunogenicity study in these subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a safety and immunogenicity study in health employees as
      detailed below:

        -  Examine adverse events of all employees after vaccination using adverse events form

        -  Examine the immunogenicity of the vaccine by collecting blood samples at days 0, 21 &amp; 42
           after vaccination (up to 500 people)

        -  Provide a detailed time course of the immune response to vaccination with a novel
           influenza H1N1 virus including the kinetics of the T-cell, B-cell and antibody responses
           in 50 volunteers

        -  Investigate the long lasting immunity induced by the vaccine

        -  Examine the ability of the vaccine to induce cross-reactive immunity to H1N1 strains.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Local and Systemic Adverse Events</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Solicited adverse events were collected on side reactions form which were filled in for 21 days after pandemic or seasonal vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immunogenicity as Determined Using Haemagglutination Inhibition Assay</measure>
    <time_frame>7, 14, 21 days post vaccination and long term follow up for 5 years</time_frame>
    <description>Antibody responses were measured using the HI assay to evaluate the rapidity and long term duration of the response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pandemic influenza H1N1 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted influenza H1N1split virion vaccine</intervention_name>
    <description>Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)
* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)</description>
    <arm_group_label>Pandemic influenza H1N1 vaccine</arm_group_label>
    <other_name>Pandemrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Signed informed consent Subjects able to understand and comply with the study protocol and
        complete the Adverse Event Form Subjects able to attend the scheduled visits for the
        kinetic study

        Exclusion Criteria:

          -  Persons with a history of anaphylaxis or serious reactions to any vaccine

          -  Person with known hypersensitivity to any of the vaccine components

          -  Persons who have had a temperature &gt;38oC during the previous 72 hours

          -  Persons who have had an acute respiratory infection during the last 7 days

          -  Suspected non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Espen Akselsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haakon Sjursen, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>N5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol. 2011 Aug;74(2):210-8. doi: 10.1111/j.1365-3083.2011.02561.x.</citation>
    <PMID>21438900</PMID>
  </reference>
  <reference>
    <citation>Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJ. A(H1N1)pdm09 vaccination of health care workers: improved immune responses in low responders following revaccination. J Infect Dis. 2012 Dec 1;206(11):1660-9. doi: 10.1093/infdis/jis589. Epub 2012 Sep 11.</citation>
    <PMID>22969149</PMID>
  </reference>
  <results_reference>
    <citation>Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, Nilsen M, Mohn K, Jul-Larsen A, Smith I, Major D, Wood J, Cox RJ. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 2010 Dec 16;29(2):266-73. doi: 10.1016/j.vaccine.2010.10.038. Epub 2010 Oct 27.</citation>
    <PMID>21034828</PMID>
  </results_reference>
  <results_reference>
    <citation>Jul-Larsen Å, Madhun AS, Brokstad KA, Montomoli E, Yusibov V, Cox RJ. The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Hum Vaccin Immunother. 2012 May;8(5):653-61. doi: 10.4161/hv.19503. Epub 2012 May 1.</citation>
    <PMID>22634440</PMID>
  </results_reference>
  <results_reference>
    <citation>Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum Vaccin Immunother. 2015;11(7):1654-62. doi: 10.1080/21645515.2015.1048939.</citation>
    <PMID>26009966</PMID>
  </results_reference>
  <results_reference>
    <citation>Eidem S, Tete SM, Jul-Larsen Å, Hoschler K, Montomoli E, Brokstad KA, Cox RJ. Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine. 2015 Aug 7;33(33):4146-54. doi: 10.1016/j.vaccine.2015.05.081. Epub 2015 Jun 7.</citation>
    <PMID>26057137</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2009</study_first_posted>
  <results_first_submitted>June 6, 2015</results_first_submitted>
  <results_first_submitted_qc>July 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2016</results_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bergen</investigator_affiliation>
    <investigator_full_name>Rebecca Cox</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>H1N1 pandemic vaccine immunogenicity safety</keyword>
  <keyword>Health employees</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HCW working at Haukeland University Hospital during the influenza pandemic in 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pandemic Influenza Vaccine (H1N1)v</title>
          <description>Pandemrix: Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)
* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Health Care Workers</title>
          <description>Received one or two doses of pandemic vaccine during 2009 pandemic and susbequent seasonal vaccination was optional</description>
        </group>
        <group group_id="B2">
          <title>Hypogammaglobulinaemic Patients</title>
          <description>Received two doses of pandemic vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="251"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local and Systemic Adverse Events</title>
        <description>Solicited adverse events were collected on side reactions form which were filled in for 21 days after pandemic or seasonal vaccination.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>solicited adverse event forms were collected from the volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>Pandemic Vaccine</title>
            <description>Pandemic Vaccine in HCW</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local and Systemic Adverse Events</title>
          <description>Solicited adverse events were collected on side reactions form which were filled in for 21 days after pandemic or seasonal vaccination.</description>
          <population>solicited adverse event forms were collected from the volunteers</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immunogenicity as Determined Using Haemagglutination Inhibition Assay</title>
        <description>Antibody responses were measured using the HI assay to evaluate the rapidity and long term duration of the response</description>
        <time_frame>7, 14, 21 days post vaccination and long term follow up for 5 years</time_frame>
        <population>Only HCW 251 were assessed for HI antibodies at 21 days post vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>HCW Pandemic Vaccine</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immunogenicity as Determined Using Haemagglutination Inhibition Assay</title>
          <description>Antibody responses were measured using the HI assay to evaluate the rapidity and long term duration of the response</description>
          <population>Only HCW 251 were assessed for HI antibodies at 21 days post vaccination</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 year follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pandemic Vaccine</title>
          <description>HCW vaccinated with pandemic vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pain at injection site</sub_title>
                <counts group_id="E1" events="196" subjects_affected="196" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Rebecca Cox</name_or_title>
      <organization>University of Bergen</organization>
      <phone>+4755974668</phone>
      <email>rebecca.cox@uib.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

